Last 12 months
Inside the activity.
0 purchase rows · 169 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 23 |
| Dec 2025 | 0 | 18 |
| Jan 2026 | 0 | 44 |
| Feb 2026 | 0 | 22 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 10 |
| May 2026 | 0 | 19 |
| Jun 2026 | 0 | 13 |
| Jul 2026 | 0 | 7 |
| Aug 2026 | 0 | 4 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 09, 2026 Filed Feb 11, 2026 21:43 UTC |
MCGIRR DAVID W JDirector
|
GiftCommon Stock | 53,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001219023-26-000002 · wk-form4_1770846185.xml · nonDerivative · entry 1 MCGIRR DAVID W J · CIK 0001219023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,323 Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · derivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,850 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · derivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,840 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 1,287 | $148.83 | $191,544.21 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 301,185 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 1,287 shares sold at prices ranging from $148.62 to $149.35 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 7,221 | $148.02 | $1,068,852.42 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 302,472 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 7,221 shares sold at prices ranging from $147.61 to $148.60 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 4,888 | $147.17 | $719,366.96 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,693 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 4,888 shares sold at prices ranging from $146.61 to $147.60 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,581 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 09, 2026 Filed Feb 11, 2026 21:42 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000013 · wk-form4_1770846139.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 308,322 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 05, 2026 Filed Feb 6, 2026 21:18 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 869 | $152.44 | $132,470.36 |
DisclosureSEC source: 0001796960-26-000010 · wk-form4_1770412728.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 83,243 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:20 UTC |
Adsett RogerChief Operating Officer
|
SaleCommon Stock | 791 | $156.17 | $123,530.47 |
DisclosureSEC source: 0001685904-26-000006 · wk-form4_1770240004.xml · nonDerivative · entry 1 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,810 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:19 UTC |
Bonstein SaraChief Financial Officer
|
SaleCommon Stock | 748 | $156.34 | $116,942.32 |
DisclosureSEC source: 0001604019-26-000006 · wk-form4_1770239979.xml · nonDerivative · entry 1 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,758 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:17 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 3,009 | $156.34 | $470,427.06 |
DisclosureSEC source: 0001402051-26-000011 · wk-form4_1770239840.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 303,882 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:15 UTC |
Smith Michael AlexanderChief Legal Officer
|
SaleCommon Stock | 640 | $156.27 | $100,012.80 |
DisclosureSEC source: 0001870278-26-000006 · wk-form4_1770239741.xml · nonDerivative · entry 1 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,397 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| February 03, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 795 | $155.77 | $123,837.15 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 7 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,112 F6 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,982 | $0.00 Strike: $65.72 | $0.00 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · derivative · entry 8 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,948 Underlying: Common Stock · 7,982 shares Expires 2035-01-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: These stock options were granted under the Company's Amended and Restated 2019 Incentive Plan, as amended. The options become exercisable based on the following vesting schedule: 25% vest on the first day of the first month following the first anniversary of the date of grant and an additional 12.5% vest every six months thereafter until fully vested. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 100 | $156.86 | $15,686.00 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 6 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,907 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 3,042 | $155.46 | $472,909.32 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 5 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,007 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 3,042 shares sold at prices ranging from $155.10 to $155.96 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 3,349 | $154.56 | $517,621.44 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 4 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 88,049 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 3,349 shares sold at prices ranging from $154.10 to $155.09 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 928 | $153.16 | $142,132.48 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 3 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 91,398 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 928 shares sold at prices ranging from $152.77 to $153.31 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 563 | $152.06 | $85,609.78 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 2 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,326 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 563 shares sold at prices ranging from $151.76 to $152.74 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 21:15 UTC |
Flammer Martina M.D.Chief Medical Officer
|
Exercise / conversionCommon Stock | 7,982 | $65.72 | $524,577.04 |
DisclosureSEC source: 0001796960-26-000008 · wk-form4_1770239710.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,889 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · derivative · entry 11 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,280 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · derivative · entry 10 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,109 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 254 | $160.70 | $40,817.80 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,891 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 254 shares sold at prices ranging from $160.58 to $160.76 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 2,229 | $159.85 | $356,305.65 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,145 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 2,229 shares sold at prices ranging from $159.55 to $160.32 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 5,967 | $158.99 | $948,693.33 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 309,374 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 5,967 shares sold at prices ranging from $158.55 to $159.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 1,243 | $158.37 | $196,853.91 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 315,341 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 1,243 shares sold at prices ranging from $157.54 to $158.53 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 1,006 | $156.80 | $157,740.80 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 316,584 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 1,006 shares sold at prices ranging from $156.53 to $157.50 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 317,590 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 20, 2026 Filed Jan 22, 2026 21:28 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000009 · wk-form4_1769117327.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 313,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 4,440 | $0.00 Strike: $17.16 | $0.00 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · derivative · entry 13 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,720 Underlying: Common Stock · 4,440 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 6,259 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · derivative · entry 12 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 81,368 Underlying: Common Stock · 6,259 shares Expires 2028-01-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F8 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: 25% vested on the first anniversary of the grant date and an additional 12.5% vested on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 315 | $174.86 | $55,080.90 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 9 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 306,891 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 297 | $172.36 | $51,190.92 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 8 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,206 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F7 · price: This is the weighted average sales price representing 297 shares sold at prices ranging from $172.26 to $172.42 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 297 | $171.31 | $50,879.07 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 7 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,503 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F6 · price: This is the weighted average sales price representing 297 shares sold at prices ranging from $171.21 to $171.52 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 160 | $170.24 | $27,238.40 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 6 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,800 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5 · price: This is the weighted average sales price representing 160 shares sold at prices ranging from $170.12 to $170.89 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 6,996 | $169.57 | $1,186,311.72 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 5 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 307,960 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4 · price: This is the weighted average sales price representing 6,996 shares sold at prices ranging from $169.11 to $170.08 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 7,176 | $168.63 | $1,210,088.88 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 4 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 314,956 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: This is the weighted average sales price representing 7,176 shares sold at prices ranging from $168.11 to $169.10 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 3,974 | $167.73 | $666,559.02 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 322,132 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: This is the weighted average sales price representing 3,974 shares sold at prices ranging from $167.11 to $168.02 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 4,440 | $17.16 | $76,190.40 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 2 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 326,106 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 12, 2026 Filed Jan 13, 2026 21:04 UTC |
Lewis WilliamDirector · Chair and CEO
|
Exercise / conversionCommon Stock | 6,259 | $30.46 | $190,649.14 |
DisclosureSEC source: 0001402051-26-000007 · wk-form4_1768338242.xml · nonDerivative · entry 1 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 321,666 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 4, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 09, 2026 Filed Jan 13, 2026 21:03 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 1,887 | $186.19 | $351,340.53 |
DisclosureSEC source: 0001796960-26-000006 · wk-form4_1768338200.xml · nonDerivative · entry 1 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 84,907 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:22 UTC |
Adsett RogerChief Operating Officer
|
SaleCommon Stock | 2,059 | $174.17 | $358,616.03 |
DisclosureSEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 3 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,601 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:21 UTC |
Bonstein SaraChief Financial Officer
|
SaleCommon Stock | 1,447 | $174.17 | $252,023.99 |
DisclosureSEC source: 0001604019-26-000004 · wk-form4_1767910881.xml · nonDerivative · entry 3 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 80,506 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:20 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 3,251 | $174.17 | $566,226.67 |
DisclosureSEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 8 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,794 F1 · kind: This transaction was effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on February 27, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:20 UTC |
Flammer Martina M.D.Chief Medical Officer
|
SaleCommon Stock | 1,660 | $173.87 | $288,624.20 |
DisclosureSEC source: 0001796960-26-000004 · wk-form4_1767910845.xml · nonDerivative · entry 7 Flammer Martina M.D. · CIK 0001796960 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,045 F5 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. F7 · price: This is the weighted average sales price representing 1,660 shares sold at prices ranging from $173.87 to $173.90 per share. The Reporting Person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:20 UTC |
Lewis WilliamDirector · Chair and CEO
|
SaleCommon Stock | 3,223 | $174.17 | $561,349.91 |
DisclosureSEC source: 0001402051-26-000005 · wk-form4_1767910807.xml · nonDerivative · entry 3 Lewis William · CIK 0001402051 · Director · Chair and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 315,407 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 08, 2026 Filed Jan 8, 2026 22:19 UTC |
Smith Michael AlexanderChief Legal Officer
|
SaleCommon Stock | 1,053 | $174.17 | $183,401.01 |
DisclosureSEC source: 0001870278-26-000004 · wk-form4_1767910777.xml · nonDerivative · entry 3 Smith Michael Alexander · CIK 0001870278 · Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,037 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:22 UTC |
Adsett RogerChief Operating Officer
|
SaleCommon Stock | 802 | $175.07 | $140,406.14 |
DisclosureSEC source: 0001685904-26-000004 · wk-form4_1767910926.xml · nonDerivative · entry 2 Adsett Roger · CIK 0001685904 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,660 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 22:21 UTC |
Bonstein SaraChief Financial Officer
|
SaleCommon Stock | 1,678 | $175.07 | $293,767.46 |
DisclosureSEC source: 0001604019-26-000004 · wk-form4_1767910881.xml · nonDerivative · entry 2 Bonstein Sara · CIK 0001604019 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 81,953 F1 · kind: Shares sold to satisfy tax withholding obligations upon the vesting of Restricted Stock Units and to cover related broker fees. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.